Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

H2APEX Group SCA Registered Shs Aktie 10989086 / LU0472835155

04.02.2026 08:00:04

EQS-News: H2APEX advances project development for large-scale “WAL Hydrogen from Lubmin” through PMC contract

EQS-News: H2APEX Group SCA / Key word(s): Miscellaneous
H2APEX advances project development for large-scale “WAL Hydrogen from Lubmin” through PMC contract

04.02.2026 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


H2APEX advances project development for large-scale “WAL Hydrogen from Lubmin” through PMC contract 

  • The IPCEI-funded WAL project will continue to be developed by H2APEX, generating predictable service revenues for the 2026 financial year
  • The 100 MW “WAL – Hydrogen from Lubmin” project is considered a strategically important IPCEI initiative in Europe and represents a central building block for scaling up the green hydrogen market in Germany

Laage, February 4, 2026 – H2APEX Energy GmbH is continuing project development for the European large-scale hydrogen project “WAL – Hydrogen from Lubmin” under a PMC contract. H2APEX thus strengthens its own planning security for the current financial year 2026.

GHS2, the project company for the major European hydrogen project ‘WAL – Hydrogen from Lubmin’, consolidates the project-relevant assets and acts as the central governance entity for implementing the WAL project. The ownership partnership between H2APEX and CIP, successfully completed last year, forms the foundation of this structure and establishes clear responsibilities regarding asset ownership, project management, and capital allocation. The awarding of the PMC package follows the positive assessment of previous project milestones and aims to further accelerate the realization of the 100 MW IPCEI project while increasing transparency in scheduling, cost control, and operational management.

“We are pleased that, through the PMC package with GHS2, we can further demonstrate to our stakeholders and investors our strategic focus on the development of hydrogen projects. It confirms the operational performance capabilities of our company and strengthens our position in the continued expansion of the WAL project,” says Peter Rössner, Managing Director of H2APEX Energy GmbH.

 

About H2APEX

The operational core of H2APEX was founded in Mecklenburg-Western Pomerania in 2000 and has focused entirely on clean hydrogen production, storage and distribution since 2012. This makes the company one of the pioneers in this field. H2APEX's goal is to become an internationally established developer and operator of hydrogen plants. In its core business, H2APEX develops, builds and sells or operates green hydrogen plants with an electrolysis capacity of up to 2 GW. These are used to decarbonise industrial value chains and produce green hydrogen. They are used, for example, in the steel, chemical and cement industries, as well as other energy-intensive industries. In addition, the company offers systems for infrastructure and logistics, particularly for industrial use in warehouses, ports and production facilities.


Contact: 

H2APEX         
Investor Relations       
Henriette Siegel        
Phone: +49 381 799902-320      
Email: investor.relations@h2apex.com     
Timmermannsstrat 2a            
18055 Rostock         
www.h2apex.com       

 

IR.on AG
Investor Relations                                                     
Frederic Hilke, Niklas Wagner
Phone:  +49 221 9140 973
E-Mail: h2apex@ir-on.com 
Mittelstr. 12-14                                                           
50672 Köln
www.ir-on.com

 



04.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: H2APEX Group SCA
19, rue de Flaxweiler
6776 Grevenmacher
Luxemburg
Phone: +352 2838 4720
Fax: +352 2838 4729
E-mail: info@h2apex.com
Internet: www.h2apex.com
ISIN: LU0472835155
WKN: A0YF5P
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate BSX
EQS News ID: 2270858

 
End of News EQS News Service

2270858  04.02.2026 CET/CEST

Analysen zu H2APEX Group SCA Registered Shs

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Longevity = mehr Rendite? Dr. Anna Erat über Healthspan & Investments – zu Gast im BX Morningcall

Im neuesten BX Morningcall ist Dr. Anna Erat zu Gast – Spezialistin für Innere Medizin, Sportmedizin, Prävention und Longevity. Gemeinsam mit Olivia Hähnel und François Bloch sprechen wir darüber, was Longevity wirklich bedeutet (Healthspan vs. Lifespan), warum es mehr ist als Biohacking und wie man seriöse Angebote von Hype unterscheidet.

Dr. Erat gibt Einblick, wie eine erste Longevity-Konsultation abläuft, welche Rolle Anamnese, Genetik/Epigenetik und Technologie/AI spielen und worauf Patientinnen und Patienten bei der Wahl eines Anbieters achten sollten. Ausserdem: Versicherung & Kostenübernahme in der Schweiz, Erwartungsdruck bei High-Performance-Klienten und ein spannender Case: Wie würde sie mit Lindsey Vonn nach einer Verletzung umgehen?

https://bxplus.ch/bx-musterportfolio/

Longevity = mehr Rendite? Dr. Anna Erat über Healthspan & Investments – zu Gast im BX Morningcall

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 14’565.14 20.00 S3JB1U
Short 14’862.98 14.00 S43BWU
Short 15’441.81 8.86 SJ1B5U
SMI-Kurs: 13’976.98 25.02.2026 16:01:42
Long 13’421.30 19.44 SJIBWU
Long 13’111.66 13.72 S18BJU
Long 12’566.39 8.94 SATBDU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com